For whom tocilizumab is used?

Tocilizumab (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist, used to treat cytokine release syndrome (CRS), systemic juvenile idiopathic arthritis (sJIA), systemic Sclerosis-associated interstitial lung disease, giant cell arteritis (GCA), and rheumatoid arthritis (RA), and subsequently, COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab is available as monotherapy or in combination with methotrexate or other nonbiologic drugs, as an intravenous infusion or subcutaneous injection.